Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

Journal of Clinical Oncology

Volumn 19, Issue 2, 2001, Pages 414-419

  Spaepen, K ^a   Stroobants, S ^a   Dupont, P ^a   Van Steenweghen, S ^a   Thomas, J ^a   Vandenberghe, P ^a   Vanuytsel, L ^a   Bormans, G ^a   Balzarini, J ^a   De Wolf Peeters, C ^a   Mortelmans, L ^a   Verhoef, G ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; COMPUTER ASSISTED TOMOGRAPHY; DEVICE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0035863387     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.2.414     Document Type: Article

References (26)

1. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
2. How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients?
3. Prognostic factors in aggressive malignant lymphomas: Description and validation of prognostic index that could identify patients requiring a more intensive therapy
4. Residual mass in lymphoma may not be residual disease
5. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma
6. Gallium scan in the evaluation of post chemotherapy mediastinal residual masses of aggressive non-Hodgkin's lymphoma
7. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma
8. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
9. Extranodal malignant lymphoma: Detection with FDG-PET versus CT
10. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose
11. Whole-body 18f-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma
12. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): Results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol
13. Maximum likelihood reconstruction for emission tomography
14. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas
15. Non-parametric estimation from incomplete observations
16. Statistical aspects of the analysis of data from retrospective studies of diseases
17. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
18. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: Significance and management
19. Gallium scans in the management of patients with Hodgkin's disease: A study of 101 patients
20. High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma
21. Gallium-67 imaging: A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma
22. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy
23. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium- 67 citrate imaging for the detection of lymphoma
24. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma
25. The role of positron emission tomography (PET) in the management of lymphoma patients
26. Whole-body positron emission tomography using F-18-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has a higher diagnostic and prognostic value than classical computed tomography scan imaging